Biomarker: Predictive or Prognostic?
Top Cited Papers
- 20 November 2015
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (33), 3968-3971
- https://doi.org/10.1200/jco.2015.63.3651
Abstract
To demonstrate that a biomarker is predictive of treatment benefit, the study requires biomarker status on all patients as well as patients who were treated with the agent of interest and patients not so treated, preferably in the context of a randomized study. A formal statistical test of the treatment-by-biomarker interaction should be significant. To establish whether a marker is purely prognostic, it needs to be demonstrated that there is a significant association between the biomarker and outcome, regardless of treatment, and that treatment effects do not depend on the biomarker. Finally, a biomarker may have both predictive and prognostic implications. These concepts are summarized in Figure 2.Keywords
This publication has 8 references indexed in Scilit:
- Genomic Analysis Reveals That Immune Function Genes Are Strongly Linked to Clinical Outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab TrialJournal of Clinical Oncology, 2015
- Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive, First-Line Metastatic Breast CancerJournal of Clinical Oncology, 2014
- Statistical and Practical Considerations for Clinical Evaluation of Predictive BiomarkersJNCI Journal of the National Cancer Institute, 2013
- Prospective Molecular Marker Analyses of EGFR and KRAS From a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2011
- Use of Archived Specimens in Evaluation of Prognostic and Predictive BiomarkersJNCI Journal of the National Cancer Institute, 2009
- Preoperative Nomogram Predicting the 10-Year Probability of Prostate Cancer Recurrence After Radical ProstatectomyJNCI Journal of the National Cancer Institute, 2006
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerThe New England Journal of Medicine, 2004
- Sample size requirements and length of study for testing interaction in a 1 × k factorial design when time-to-failure is the outcomeControlled Clinical Trials, 1993